BioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on the development of small molecules to inhibit biofilm formation, which causes 80% of chronic and recurrent infections.
BioTryp’s technology targets bacteria’s key defense mechanism, offering an alternative to traditional antibiotic treatments. The company’s small molecules are designed to block the communication process that bacteria use to make a biofilm.
The first indication for the company’s innovative approach is Urinary Tract Infections (UTIs), aiming to revolutionize UTI treatment by targeting bacterial biofilms forming on the bladder wall and urinary catheters. UTIs are the most common bacterial infection and the leading cause of bloodstream infections. Affecting 1 in 2 women and 1 in 10 men, UTIs are responsible for 17% of all hospital-acquired bloodstream infections.
Subscribe for alerts on new companies featured on Startups.Bio
The biotechnology sector is advancing rapidly, fueled by significant venture capital investments that are enabling companies to achieve major breakthroughs. To stay informed about the latest funding activities and discover …
Founded in 2024, Analona Therapeutics is a biotech company located in Denmark focused on developing innovative antibody-based therapies for pancreatic cancer. The company is built on cutting-edge research from the …
U-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility. Millions of women around the world face the emotional and financial toll of age-related infertility. As more individuals choose to start …
Bastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class Treg cell therapies, which can target the root causes of inflammatory disorders and autoimmune diseases. Bastion's GRIT™ (Genetically …